SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track
The company’s EBITDA margin remained resilient above 20%
The company’s EBITDA margin remained resilient above 20%
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
HCG clinicians contributing to one of the largest bodies of oncology research from India
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
Subscribe To Our Newsletter & Stay Updated